Ensysce Biosciences, Inc. (NASDAQ:ENSC) Sees Large Decline in Short Interest

Posted by Brenda Bartman on Jun 10th, 2026

Ensysce Biosciences, Inc. (NASDAQ:ENSC – Get Free Report) was the recipient of a significant drop in short interest during the month of May. As of May 29th, there was short interest totaling 50,601 shares, a drop of 93.8% from the May 14th total of 814,605 shares. Based on an average daily volume of 874,310 shares, the short-interest ratio is presently 0.1 days. Currently, 0.3% of the company’s shares are short sold.

Ensysce Biosciences Stock Up 0.4%

Shares of ENSC traded up $0.00 during trading on Tuesday, reaching $0.25. 1,129,772 shares of the company traded hands, compared to its average volume of 1,255,055. Ensysce Biosciences has a twelve month low of $0.23 and a twelve month high of $2.75. The stock has a market cap of $3.90 million, a PE ratio of -0.08 and a beta of 0.83. The stock has a 50-day simple moving average of $0.39 and a 200-day simple moving average of $0.71.

Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.21. Ensysce Biosciences had a negative net margin of 250.39% and a negative return on equity of 766.45%. The business had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $1.00 million. On average, equities research analysts predict that Ensysce Biosciences will post -1.98 EPS for the current year.

Institutional Investors Weigh In On Ensysce Biosciences

Institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new stake in shares of Ensysce Biosciences during the third quarter valued at about $34,000. Virtu Financial LLC acquired a new position in shares of Ensysce Biosciences in the third quarter valued at approximately $34,000. DRW Securities LLC grew its holdings in shares of Ensysce Biosciences by 42.4% in the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after purchasing an additional 29,336 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its holdings in shares of Ensysce Biosciences by 100.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after purchasing an additional 75,000 shares in the last quarter. 5.63% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

View Our Latest Stock Report on ENSC

Ensysce Biosciences Company Profile

(Get Free Report)

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.